BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1631603)

  • 1. Towards a capitation formula for competing health insurers. An empirical analysis.
    van Vliet RC; van de Ven WP
    Soc Sci Med; 1992 May; 34(9):1035-48. PubMed ID: 1631603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capitation payments based on prior hospitalizations.
    van Vliet RC; van de Ven WP
    Health Econ; 1993 Jul; 2(2):177-88. PubMed ID: 8261038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiyear diagnostic information from prior hospitalization as a risk-adjuster for capitation payments.
    Lamers LM; van Vliet RC
    Med Care; 1996 Jun; 34(6):549-61. PubMed ID: 8656721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-adjusted capitation payments for catastrophic risks based on multi-year prior costs.
    van Barneveld EM; van Vliet RC; van de Ven WP
    Health Policy; 1997 Feb; 39(2):123-35. PubMed ID: 10165042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-adjusted capitation payments: developing a diagnostic cost groups classification for the Dutch situation.
    Lamers LM
    Health Policy; 1998 Jul; 45(1):15-32. PubMed ID: 10183010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mandatory pooling as a supplement to risk-adjusted capitation payments in a competitive health insurance market.
    Van Barneveld EM; Lamers LM; van Vliet RC; van de Ven WP
    Soc Sci Med; 1998 Jul; 47(2):223-32. PubMed ID: 9720641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adjusted capitation based on the Diagnostic Cost Group Model: an empirical evaluation with health survey information.
    Lamers LM
    Health Serv Res; 1999 Feb; 33(6):1727-44. PubMed ID: 10029506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplementary insurance as a switching cost for basic health insurance: Empirical results from the Netherlands.
    Willemse-Duijmelinck DMID; van de Ven WPMM; Mosca I
    Health Policy; 2017 Oct; 121(10):1085-1092. PubMed ID: 28855064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in the persistence of health expenditures and the implications for the design of capitation payments in Taiwan.
    Ku LJ; Chiou MJ; Liu LF
    J Health Serv Res Policy; 2015 Jul; 20(3):146-53. PubMed ID: 25829410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk sharing as a supplement to imperfect capitation: a tradeoff between selection and efficiency.
    van Barneveld EM; Lamers LM; van Vliet RC; van de Ven WP
    J Health Econ; 2001 Mar; 20(2):147-68. PubMed ID: 11252368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ignoring small predictable profits and losses: a new approach for measuring incentives for cream skimming.
    van Barneveld EM; Lamers LM; van Vliet RC; van de Ven WP
    Health Care Manag Sci; 2000 Feb; 3(2):131-40. PubMed ID: 10780281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-adjusted Medicare capitation rates using ambulatory and inpatient diagnoses.
    Weiner JP; Dobson A; Maxwell SL; Coleman K; Starfield B; Anderson GF
    Health Care Financ Rev; 1996; 17(3):77-99. PubMed ID: 10158737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacy costs groups: a risk-adjuster for capitation payments based on the use of prescribed drugs.
    Lamers LM
    Med Care; 1999 Aug; 37(8):824-30. PubMed ID: 10448725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposing the true risks of capitation financed healthcare.
    Cox T
    J Healthc Risk Manag; 2011; 30(4):34-41. PubMed ID: 21506200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The high costs of death: should health plans get higher payments when members die?
    van Vliet RC; Lamers LM
    Med Care; 1998 Oct; 36(10):1451-60. PubMed ID: 9794339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-adjusted capitation: recent experiences in The Netherlands.
    van de Ven WP; van Vliet RC; van Barneveld EM; Lamers LM
    Health Aff (Millwood); 1994; 13(5):120-36. PubMed ID: 7868016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growing importance of capitation in Switzerland.
    Beck K
    Health Care Manag Sci; 2000 Feb; 3(2):111-9. PubMed ID: 10780279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can we prevent cream skimming in a competitive health insurance market? The great challenge for the 90's.
    Van de Ven WP; Van Vliet RC
    Dev Health Econ Public Policy; 1992; 1():23-46. PubMed ID: 10151748
    [No Abstract]   [Full Text] [Related]  

  • 19. Reimbursing insurance carriers: the case of 'MUFACE' in the Spanish health care system.
    Pellisé L
    Health Econ; 1994; 3(4):243-53. PubMed ID: 7994324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a reinforced agency role of health insurers in Belgium and The Netherlands.
    Schut FT; van Doorslaer EK
    Health Policy; 1999 Jul; 48(1):47-67. PubMed ID: 10539585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.